LAMP2 and plasma cell myeloma: Bortezomib, a proteosome inhibitor used in the treatment of multiple myeloma, induced the colocalization of LC3 and Lysosome Associated Membrane Protein 2 (LAMP2), a lysosome marker, in NCI-H929 cells by immunofluorescent microscopy [24].